Signaturefd, LLC Apellis Pharmaceuticals, Inc. Transaction History

Signaturefd, LLC

$5.2 Billion
Q3 2024

A detailed history of Signaturefd, LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 257 shares of APLS stock, worth $6,728. This represents 0.0% of its overall portfolio holdings.

Number of Shares

257

Previous 356 27.81%

Holding current value

$6,728

Previous $13,000 46.15%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 21, 2024	SELL	$28.84 - $41.15 $2,855 - $4,073	-99 Reduced 27.81%	257 $7,000
Q2 2024 Jul 29, 2024	SELL	$38.07 - $59.71 $27,829 - $43,648	-731 Reduced 67.25%	356 $13,000
Q1 2024 May 03, 2024	BUY	$55.39 - $72.47 $23,042 - $30,147	416 Added 62.0%	1,087 $63,000
Q4 2023 Jan 31, 2024	BUY	$37.14 - $64.82 $4,122 - $7,195	111 Added 19.82%	671 $40,000
Q3 2023 Nov 03, 2023	BUY	$23.65 - $89.22 $9,247 - $34,885	391 Added 231.36%	560 $21,000
Q2 2023 Aug 01, 2023	BUY	$76.68 - $93.31 $4,600 - $5,598	60 Added 55.05%	169 $15,000
Q1 2023 Apr 28, 2023	BUY	$46.59 - $66.96 $1,584 - $2,276	34 Added 45.33%	109 $7,000
Q4 2022 Jan 27, 2023	SELL	$43.24 - $61.04 $129 - $183	-3 Reduced 3.85%	75 $3,000
Q3 2022 Nov 08, 2022	BUY	$44.76 - $69.66 $1,208 - $1,880	27 Added 52.94%	78 $5,000
Q2 2022 Aug 10, 2022	SELL	$35.07 - $59.21 $1,437 - $2,427	-41 Reduced 44.57%	51 $2,000
Q1 2022 May 02, 2022	BUY	$35.46 - $54.12 $3,262 - $4,979	92 New	92 $5,000
Q1 2021 Apr 30, 2021	SELL	$40.8 - $57.39 $938 - $1,319	-23 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$30.79 - $57.2 $708 - $1,315	23 New	23 $1,000

Others Institutions Holding APLS

# of Institutions

308

Shares Held

115M

Call Options Held

3.85M

Put Options Held

1.09M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.88B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account